Rezdiffra (Resmetirom) Complete Drug-Drug Interaction Profile

How Resmetirom Works and Why Interactions Matter

Resmetirom selectively activates the thyroid hormone receptor beta isoform concentrated in hepatocytes, driving mitochondrial fatty acid oxidation and reducing hepatic de novo lipogenesis. This selectivity over THR-α (the isoform that governs cardiac rate and bone turnover) is what separates it from exogenous T3 or T4 therapy. The MAESTRO-NASH trial (N=966) demonstrated MASH resolution without fibrosis worsening in 25.9% of patients on the 80 mg dose versus 9.7% on placebo at 52 weeks (1).

Because patients with MASH commonly carry comorbid type 2 diabetes, dyslipidemia, and hypothyroidism, resmetirom will frequently be co-administered with statins, thiazolidinediones, GLP-1 receptor agonists, and levothyroxine. Its dual role as a CYP2C8 inhibitor and OATP1B1/1B3 inhibitor creates pharmacokinetic collision points with several of these drugs. Understanding each interaction by mechanism, not just by drug name, allows clinicians to anticipate risk even for agents not yet studied in formal DDI trials (2).

CYP450-Mediated Interactions: CYP2C8 Is the Central Concern

Resmetirom inhibits CYP2C8 in vitro and in vivo. This is the single most clinically relevant enzymatic interaction. CYP2C8 metabolizes pioglitazone, repaglinide, amodiaquine, and (partially) paclitaxel. According to the FDA prescribing information, co-administration with repaglinide increased repaglinide AUC by approximately 1.7-fold, raising hypoglycemia risk (2).

Pioglitazone deserves special attention. Many MASH patients receive pioglitazone off-label based on AASLD guidance recommending it for biopsy-proven NASH (3). CYP2C8 inhibition by resmetirom could increase pioglitazone exposure, amplifying fluid retention and weight gain risks. No formal AUC data for this pair have been published, but the FDA label advises monitoring and possible dose reduction of CYP2C8 substrates.

Resmetirom is itself metabolized by CYP3A4 and CYP2C8. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir-boosted HIV protease inhibitors) may increase resmetirom plasma levels, though the label does not mandate dose adjustment based on currently available data. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort) may reduce resmetirom efficacy by lowering exposure below the therapeutic threshold (2). Rifampin is particularly relevant because patients with MASH and concurrent tuberculosis in endemic regions may receive prolonged rifampin-based regimens.

Statin Interactions via OATP1B1/1B3 Inhibition

Resmetirom inhibits the hepatic uptake transporters OATP1B1 and OATP1B3. These are the same transporters responsible for clearing statins from portal blood into hepatocytes, and their inhibition is a well-documented mechanism behind statin-related myopathy risk from drugs like cyclosporine and gemfibrozil (4).

In the formal DDI study, resmetirom approximately doubled rosuvastatin AUC. The FDA label recommends limiting rosuvastatin to 20 mg daily when co-prescribed with Rezdiffra. This matters in practice: MASH patients frequently require high-intensity statin therapy for cardiovascular risk reduction, and rosuvastatin 40 mg is a common prescription in this population (2).

Other OATP1B1/1B3 substrates warrant caution as well. Atorvastatin, pitavastatin, and pravastatin are all OATP substrates to varying degrees. Although formal interaction studies with these specific statins have not been published, the transporter-based mechanism predicts increased systemic exposure for each of them. Pravastatin, being entirely dependent on OATP-mediated hepatic uptake without significant CYP metabolism, may be especially sensitive (4).

A practical statin-selection framework for patients starting Rezdiffra: if the patient is on rosuvastatin 40 mg, reduce to 20 mg and recheck LDL at 6 weeks. If the patient requires high-intensity therapy above the rosuvastatin 20 mg cap, consider switching to atorvastatin 40-80 mg while monitoring CK at baseline and 3 months. Fluvastatin, metabolized primarily by CYP2C9 with minimal OATP dependence, is theoretically the least affected, though clinical outcome data in combination with resmetirom do not yet exist.

Thyroid Hormone Axis Interactions

Resmetirom suppresses serum TSH by 20-40% and reduces circulating T4 levels through enhanced hepatic thyroid hormone clearance. In euthyroid patients, this rarely produces clinical symptoms because THR-α in cardiac and skeletal tissue sees no increased agonism (1). The problem emerges when patients are already on exogenous thyroid hormone replacement.

Hypothyroidism affects roughly 15-20% of patients with MASH, per cross-sectional data linking subclinical hypothyroidism to NAFLD/MASH progression (5). A patient on levothyroxine who starts resmetirom may see TSH fall below the reference range, prompting unnecessary dose reduction of levothyroxine. Alternatively, the enhanced hepatic clearance of T4 could create a net wash, leaving TSH near baseline. The FDA label recommends checking thyroid function before initiation, at 4-8 weeks, and periodically thereafter (2).

Amiodarone represents a higher-risk combination. Amiodarone contains 37% iodine by weight and can cause both hyper- and hypothyroidism through Wolff-Chaikoff and Jod-Basedow effects (6). Adding a THR-β agonist to a patient with amiodarone-loaded tissue iodine stores creates an unpredictable thyroid axis response. No formal study exists for this combination. Until data emerge, prescribers should monitor free T4, free T3, and TSH every 4-6 weeks for the first 6 months of co-administration.

Anticoagulant and Antiplatelet Interactions

Thyroid hormones increase the catabolism of vitamin K-dependent clotting factors. Exogenous T3 raises warfarin sensitivity, a well-established clinical observation (7). Resmetirom's selective THR-β agonism theoretically produces a milder effect than systemic T3, but the FDA label still warns about potential INR elevation in warfarin-treated patients and recommends closer INR monitoring when initiating or adjusting Rezdiffra dose (2).

Direct oral anticoagulants (DOACs) do not rely on vitamin K metabolism and are not expected to show the same pharmacodynamic interaction. Apixaban is a CYP3A4 and P-gp substrate, and resmetirom has not demonstrated clinically meaningful P-gp inhibition. Rivaroxaban, also CYP3A4/P-gp dependent, should be similarly unaffected based on current mechanistic understanding. No dose adjustment is recommended for DOACs (2).

GLP-1 Receptor Agonists and Other Diabetes Therapies

The co-prescription of resmetirom with GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) is increasingly common. Both drug classes target overlapping MASH and metabolic populations. No pharmacokinetic interaction is expected: GLP-1 RAs are peptides cleared by proteolytic degradation and renal elimination, not by hepatic CYP enzymes or OATP transporters (8).

Metformin is similarly low-risk. It undergoes no hepatic metabolism and is cleared renally via OCT2 and MATE transporters. Resmetirom has not shown inhibition of these transporters (2).

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are glucuronidated by UGT enzymes with minimal CYP involvement. No interaction is anticipated, and none has been reported in MAESTRO-NASH subgroup analyses where SGLT2 inhibitor use was permitted (1).

The exception in the diabetes pharmacopeia is repaglinide (CYP2C8 substrate, discussed above) and pioglitazone. Sulfonylureas are primarily CYP2C9 substrates and are not expected to interact with resmetirom, though glimepiride has partial CYP2C8 contribution, warranting glucose monitoring during the first weeks of co-administration.

Immunosuppressants and Transplant Medications

Liver transplant recipients with recurrent MASH represent a growing clinical scenario. Tacrolimus and cyclosporine are both CYP3A4 substrates. Resmetirom's mild CYP3A4 induction potential (observed at supratherapeutic doses in preclinical data) could theoretically reduce tacrolimus trough levels, risking graft rejection. No human DDI study has been conducted for this pair (2).

Cyclosporine itself is an OATP1B1 inhibitor. Adding resmetirom (also an OATP1B1 inhibitor) to cyclosporine could produce additive transporter inhibition, substantially increasing statin exposure if all three drugs are co-prescribed. This triple combination (cyclosporine + resmetirom + rosuvastatin) should be considered contraindicated until formal PK data are available. The combination of cyclosporine and rosuvastatin alone already carries a labeled maximum rosuvastatin dose of 5 mg daily (4).

Mycophenolate mofetil undergoes glucuronidation and enterohepatic recirculation via OATP transporters. Resmetirom could theoretically alter mycophenolic acid exposure through OATP1B1/1B3 inhibition, though clinical significance is unknown. Monitoring of mycophenolate trough levels is prudent during the first 8-12 weeks of combination therapy.

Bile Acid Sequestrants and UDCA

Bile acid sequestrants (cholestyramine, colesevelam, colestipol) bind drugs nonspecifically in the gut lumen. Resmetirom is an oral drug absorbed from the GI tract, and co-administration with bile acid sequestrants could reduce its bioavailability. The FDA label recommends dosing resmetirom at least 4 hours before or 4 hours after bile acid sequestrants (2). This mirrors the established spacing rule for levothyroxine.

Ursodeoxycholic acid (UDCA) is frequently prescribed in patients with cholestatic liver disease overlapping with MASH. UDCA does not significantly affect CYP450 enzymes or OATP transporters and is not expected to interact with resmetirom pharmacokinetically (9).

Interactions with Hepatotoxic Agents

Resmetirom carries a monitoring recommendation for hepatotoxicity (ALT, AST, and bilirubin at baseline, during dose titration, and periodically thereafter). Co-prescribing other hepatotoxic drugs intensifies this monitoring need. Relevant agents include methotrexate (used for rheumatoid arthritis or psoriasis in MASH patients), isoniazid, valproic acid, and high-dose acetaminophen.

No pharmacokinetic interaction has been demonstrated between resmetirom and acetaminophen. The concern is purely additive hepatic stress. The Endocrine Society and AASLD have not yet issued formal guidance on combination hepatotoxicity monitoring specifically for resmetirom, but the general principle of stacking liver-injury risk applies (3).

Practical Monitoring Protocol for High-Risk Combinations

For clinicians starting Rezdiffra in a polypharmacy setting, the following monitoring sequence covers the major interaction risks. Check TSH, free T4, hepatic panel, fasting lipids, and INR (if on warfarin) at baseline. Repeat TSH and hepatic panel at week 4 and week 12. Repeat INR within 7-10 days of initiation for warfarin patients. Recheck fasting lipids at week 12 to assess whether statin dose adjustment has achieved target LDL. Monitor CK if the patient remains on any statin. Repeat full panel at 6 months and annually thereafter (2).

Patients on three or more interacting medications (for example, levothyroxine + rosuvastatin + pioglitazone) may benefit from a pharmacist-led medication therapy management consult before and 90 days after Rezdiffra initiation. The MAESTRO-NASH trial excluded patients on amiodarone and organ transplant recipients, so real-world evidence for these populations remains limited to case-level experience (1).